Eugen F. Mesaros - Concepedia

Author

Eugen F. Mesaros

Also Known As

E. MESAROS, E.F. Mesaros, Eugen F Mesaros, Eugen F. Mesaros, Eugen Mesaros, Eugen Mesaros,, Mesaros, E., Mesaros, E.F., Mesaros, Eugen F.

Publications

786

Citations

H-Index

Concepts

All Affiliations

Babeș-Bolyai University University of Pennsylvania Université de Rouen Normandie Monell Chemical Senses Center Teva Pharmaceuticals (United States)

About

Eugen F. Mesaros is an author at Babeș-Bolyai University specializing in pharmacology, medicinal chemistry, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	228
2	Engineering	2	2	105
3	Natural Sciences	2	2	119
4	Biochemistry	2	2	119
5	Biomolecular Engineering	2	2	105

Eugen F. Mesaros

Publications

634

Citations

H-Index

Page 1

	Year	Citations
Evolution of a Total Synthesis of (−)-Kendomycin Exploiting a Petasis−Ferrier Rearrangement/Ring-Closing Olefin Metathesis Strategy Amos B. Smith, Eugen F. Mesaros, Emmanuel A. Meyer Journal of the American Chemical Society Medicinal ChemistryBiosynthesisBioorganic ChemistryEngineeringBiochemistry	2006	94
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK) Gregory R. Ott, Mangeng Cheng, Keith S. Learn, Journal of Medicinal Chemistry Tumor BiologyClinical Candidate Cep-37440Lymphoid NeoplasiaOncologyMetabolic Stability	2016	88
Total Synthesis of (−)-Kendomycin Exploiting a Petasis−Ferrier Rearrangement/Ring-Closing Olefin Metathesis Synthetic Strategy Amos B. Smith, Eugen F. Mesaros, Emmanuel A. Meyer Journal of the American Chemical Society	2005	74
A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-<i>a</i>]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Journal of Medicinal Chemistry	2012	62
2,7-Disubstituted-pyrrolo[2,1-<i>f</i>][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity Gregory R. Ott, Gregory J. Wells, Tho V. Thieu, Journal of Medicinal Chemistry Tumor BiologyMedicinal ChemistryDiversity Oriented SynthesisPharmaceutical ChemistryMedicine	2011	42
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes Robert E. Lee Trout, Allison L. Zulli, Eugen F. Mesaros, Journal of Medicinal Chemistry	2021	41
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models Eugen F. Mesaros, Jason P. Burke, Jonathan D. Parrish, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPharmacological StudyBioavailable Alk InhibitorsMedicineAntitumor Efficacy	2010	34
Diastereoselective Conjugate Additions to π-Allylmolybdenum Complexes: A Stereocontrolled Route to 3,4,5-Trisubstituted γ-Butyrolactones Anthony J. Pearson, Eugen F. Mesaros Organic Letters	2002	27
Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-<i>f</i>][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors Eugen F. Mesaros, Tho V. Thieu, Gregory J. Wells, Journal of Medicinal Chemistry Pharmaceutical ScienceStable Alk InhibitorsPharmacotherapyPiperidine-derived AnaloguesPharmaceutical Chemistry	2011	25
Study on the atropisomerism of some new 2-aryl-1,3-dioxanes Ion Grosu, Gérard Plé, Sorin Mager, Tetrahedron Organic Material ChemistryOrganic ChemistryNew 2-Aryl-1,3-dioxanesChemistryLinear Chain Compound	1998	24

Page 1